Alzamend Neuro, Inc.

Business Summary

PART I In this Annual Report, unless the context requires otherwise, references to the Company, Alzamend, we, our company and us refer to Alzamend Neuro, Inc., a Delaware corporation and its subsidiary. Company Overview We are a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). With our two product candidates, we aim t...

Next Earnings

Q2 FY2026 — expected 2026-09-19

Key Facts from Earnings Calls

Annual Reports (10-K)

Quarterly Reports (10-Q)

Recent Current Reports (8-K)

109 total filings indexed. 82 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

Company Identity

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API: